Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pravin R Jadhav

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|July 10, 2012
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: application to drug developmentJing Fang, Pravin R Jadhav
Journal of Pharmacokinetics and Pharmacodynamics|June 28, 2012
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a frameworkJing Fang, Pravin R Jadhav
Journal of Clinical Pharmacology|October 1, 2010
The need for modeling and simulation to design clinical investigations in childrenPravin R Jadhav, Steven E Kern
The AAPS Journal|December 16, 2005
A new equivalence based metric for predictive check to qualify mixed-effects modelsPravin R Jadhav, Jogarao V S Gobburu
Pharmaceutical Statistics|July 18, 2009
Leveraging prior quantitative knowledge in guiding pediatric drug development: a case studyPravin R Jadhav, Jialu Zhang, Jogarao V S Gobburu
Journal of Clinical Pharmacology|December 14, 2011
Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studiesYaning Wang, Pravin R Jadhav, Mallika Lala, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2012
Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisionsJiang Liu, Jeffry Florian, Debra Birnkrant, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 13, 2006
Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blockerPravin R Jadhav, Henrik Agersø, Christoffer W Tornøe, et al.
Clinical Pharmacology and Therapeutics|April 27, 2018
Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to RealityPrajakti A Kothare, Pravin R Jadhav, Pankaj Gupta, et al.
Clinical and Translational Science|May 17, 2018
Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient CareBrandon Swift, Lokesh Jain, Craig White, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Pharmacokinetics and Pharmacodynamics|July 10, 2012
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part II: application to drug developmentJing Fang, Pravin R Jadhav
Journal of Pharmacokinetics and Pharmacodynamics|June 28, 2012
From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a frameworkJing Fang, Pravin R Jadhav
Journal of Clinical Pharmacology|October 1, 2010
The need for modeling and simulation to design clinical investigations in childrenPravin R Jadhav, Steven E Kern
The AAPS Journal|December 16, 2005
A new equivalence based metric for predictive check to qualify mixed-effects modelsPravin R Jadhav, Jogarao V S Gobburu
Pharmaceutical Statistics|July 18, 2009
Leveraging prior quantitative knowledge in guiding pediatric drug development: a case studyPravin R Jadhav, Jialu Zhang, Jogarao V S Gobburu
Journal of Clinical Pharmacology|December 14, 2011
Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studiesYaning Wang, Pravin R Jadhav, Mallika Lala, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2012
Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisionsJiang Liu, Jeffry Florian, Debra Birnkrant, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 13, 2006
Semi-mechanistic pharmacodynamic modeling for degarelix, a novel gonadotropin releasing hormone (GnRH) blockerPravin R Jadhav, Henrik Agersø, Christoffer W Tornøe, et al.
Clinical Pharmacology and Therapeutics|April 27, 2018
Harnessing the Potential of Emerging Digital Health and Biological Sampling Technologies for Clinical Drug Development: Promise to RealityPrajakti A Kothare, Pravin R Jadhav, Pankaj Gupta, et al.
Clinical and Translational Science|May 17, 2018
Innovation at the Intersection of Clinical Trials and Real-World Data Science to Advance Patient CareBrandon Swift, Lokesh Jain, Craig White, et al.
Pageof 2